Skip to content

Efficacy of CRS model combining serum anti-PLA2R antibody and GRS score for diagnosis and prognosis of iMN

Efficacy of CRS model combining serum anti-PLA2R antibody and GRS score for diagnosis and prognosis of iMN

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058162
Enrollment
Unknown
Registered
2022-03-31
Start date
2022-05-01
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic membranous nephropathy

Interventions

Gold Standard:Chronic kidney disease was first diagnosed according to the presence of edema, proteinuria, hypoproteinemia, hyperlipidemia, etc. Kidney biopsy was performed on the basis of chronic kidn
Index test:Serum creatinine, serum albumin, cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, serum IgG, serum IgA, serum IgM, complement C3, complement C4 were determined

Sponsors

Yuebei People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. From March 2022 to March 2023, patients who underwent renal biopsy for indications of nephropathy were included, and those who met the inclusion and exclusion criteria were screened; 2. Aged >=18 years old, and did not receive immunosuppression within 6 months before biopsy drug therapy; 3. Expected follow-up for more than 6 months.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Anti-PLA2R antibody;Proteinuria was quantified at 24h;Resistance to THSD7A antibodies;

Countries

China

Contacts

Public ContactMin He

Yuebei People's Hospital

minhe20030701@163.com+86 13680069382

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026